Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of the current burden of HF, and the prevalence is continuing to rise. In contrast to HF with reduced ejection fraction (HFrEF) there are no clinically effective evidence based therapies for HFpEF. The principal p...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-09-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fcvm.2019.00143/full |
id |
doaj-1c466c9d067d47a7a6c971b4524a5a5f |
---|---|
record_format |
Article |
spelling |
doaj-1c466c9d067d47a7a6c971b4524a5a5f2020-11-25T02:25:26ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2019-09-01610.3389/fcvm.2019.00143464015Interatrial Shunt Device for Heart Failure With Preserved Ejection FractionDavid M. KayeShane NanayakkaraHeart failure with preserved ejection fraction (HFpEF) accounts for approximately half of the current burden of HF, and the prevalence is continuing to rise. In contrast to HF with reduced ejection fraction (HFrEF) there are no clinically effective evidence based therapies for HFpEF. The principal pathophysiologic disorder is an elevation of left atrial pressure, most notable during physical activity, which results from impaired left ventricular diastolic reserve, and increased left atrial stiffness. This review outlines the clinical development of a potential device based therapy for HFpEF, the interatrial shunt device (IASD).https://www.frontiersin.org/article/10.3389/fcvm.2019.00143/fullheart failurediastolic dysfunctionstructural heart deviceclinical trialcardiac catheter interventional treatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
David M. Kaye Shane Nanayakkara |
spellingShingle |
David M. Kaye Shane Nanayakkara Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction Frontiers in Cardiovascular Medicine heart failure diastolic dysfunction structural heart device clinical trial cardiac catheter interventional treatment |
author_facet |
David M. Kaye Shane Nanayakkara |
author_sort |
David M. Kaye |
title |
Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction |
title_short |
Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction |
title_full |
Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction |
title_fullStr |
Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction |
title_full_unstemmed |
Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction |
title_sort |
interatrial shunt device for heart failure with preserved ejection fraction |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Cardiovascular Medicine |
issn |
2297-055X |
publishDate |
2019-09-01 |
description |
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of the current burden of HF, and the prevalence is continuing to rise. In contrast to HF with reduced ejection fraction (HFrEF) there are no clinically effective evidence based therapies for HFpEF. The principal pathophysiologic disorder is an elevation of left atrial pressure, most notable during physical activity, which results from impaired left ventricular diastolic reserve, and increased left atrial stiffness. This review outlines the clinical development of a potential device based therapy for HFpEF, the interatrial shunt device (IASD). |
topic |
heart failure diastolic dysfunction structural heart device clinical trial cardiac catheter interventional treatment |
url |
https://www.frontiersin.org/article/10.3389/fcvm.2019.00143/full |
work_keys_str_mv |
AT davidmkaye interatrialshuntdeviceforheartfailurewithpreservedejectionfraction AT shanenanayakkara interatrialshuntdeviceforheartfailurewithpreservedejectionfraction |
_version_ |
1724851389879812096 |